Search Results 1551-1560 of 16446 for alt

  1. A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors - Mayo Clinic

    Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 x ULN (≤5 × ULN for patients with known hepatic metastases). 11. Adequate renal ...

  2. News Releases - 2015 Archives

    Rochester, Minn. — Frailty can affect people of all ages and demographics. Defined simply as “an increased vulnerability to adverse health outcomes,” frailty ...

  3. Minnesota - 2015 Archives - Mayo Clinic News Network

    Rochester, Minn. — Frailty can affect people of all ages and demographics. Defined simply as “an increased vulnerability to adverse health outcomes,” frailty ...

  4. A Study of LOXO-292 in Patients with Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer - Mayo Clinic

    ALT and AST ≤ 2.5 × the upper limit of normal (ULN) or ≤ 5 × ULN with documented liver involvement (such as liver metastasis or a primary biliary tumor); and ...

  5. Liver transplant - Doctors & Departments - Mayo Clinic

    Joo DJ, et al. Bioartificial liver support for acute liver failure. Annals of Liver Transplantation. 2025; doi:10.52604/alt.25.0004. Taner T, et al. Summary of ...

  6. Liver transplant - Doctors & Departments - Mayo Clinic

    Joo DJ, et al. Bioartificial liver support for acute liver failure. Annals of Liver Transplantation. 2025; doi:10.52604/alt.25.0004. Taner T, et al. Summary of ...

  7. A Study to Evaluate Effectiveness and Safety of Ustekinumab Re-induction Therapy in Participants With Moderate to Severely Active Crohn's Disease (POWER) - Mayo Clinic

    Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase levels ≤ 2 times the upper limit of normal for the laboratory ...

  8. Medical Research & Education - Mayo Clinic News Network

    ROCHESTER, Minn. — Mayo Clinic researchers have developed a smartwatch-based alert system that signals parents at the earliest signs of a tantrum in ...

  9. A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies - Mayo Clinic

    AST/ALT ≤ 2 x ULN. If documented liver metastases, then ≤ 5X ULN;; Bilirubin: For monotherapy and pembrolizumab combination therapy cohorts: ≤ 2 x ULN; or ...

  10. A Study to Evaluate DS-8201a Combined with Olaparib in HER2-Expressing Cancers with Expansion in Endometrial Cancer Patients Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer - Mayo Clinic

    AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN;; International Normalized ratio ≤ 1.5 × ULN (INR)/Prothrombin time (PT) and activated partial thromboplastin ...